by Institution Author "Akbayır, Ece"
Now showing items 1-4 of 4
-
Assessment of short-term ocrelizumab treatment impact on regulatory immune cell subsets through intracellular cytokine measurement in patients with multiple sclerosis
Akbayır, Ece; Karaaslan, Zerrin; Türkoğlu, Recai; Kızılay, Tuğçe; Yıldız, Ruziye Erol; Özkan-Yaşargün, Duygu; Yılmaz, Vuslat; Tüzün, Erdem (SAGE PUBLICATIONS LTD, 2025)Meeting Abstract -
B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple Sclerosis
Akbayır, Ece; Kızılay, Tuğçe; Erol, Ruziye; Özkan Yaşargün, Duygu; Tüzün, Erdem; Yılmaz, Vuslat; Türkoğlu, Recai (INT INST ANTICANCER RESEARCH, 2025)Background/Aim: Ocrelizumab, a CD20-targeting monoclonal antibody, is used for treatment of multiple sclerosis. The aim of this study was to explore the utility of peripheral blood cell subsets in prediction of treatment ... -
Baseline eronufilmniaet light chain and brain-derived neurotrophic factor levels predict development of aggressive multiple sclerosis
Yıldız, Ruziye Erol; Akbayır, Ece; Kızılay, Tuğçe; Ersöz, Ayça Simay; Yaşargün, Duygu Özkan; Süer, Devran; Yılmaz, Vuslat; Tüzün, Erdem; Türkoğlu, Recai (Tubitak Scientific & Technological Research Council Turkey, 2025)Background/aim: Patients with multiple sclerosis (MS) may present with a rapidly disabling clinical course in the first few years of disease. It is imperative to find biomarkers to predict patients with aggressive MS (AMS) ...
